ERBB2 and breast cancer: In HER2+ breast cancer, inhibition with lapatinib increases the expression of HER2 and improves the efficacy of immune system mediated cytotoxicity induced by the HER2-targeting antibody trastuzumab (Scaltriti et al., 2009).